Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Novo Nordisk sold fewer of its weight loss and diabetes drugs than expected in the second quarter, as the Ozempic and Wegovy maker faced supply constraints and increased competition.
Sales increased 25 per cent to DKr68bn ($9.94bn) in the period, below the 26.7 per cent pace forecast by analysts. Net profit for the quarter was DKr20.5bn, below expectations of DKr21.3bn.
The company also tweaked its guidance for the year ahead and now expects sales to increase 22 to 28 per cent, compared with previous guidance of 19 to 27 per cent. However, operating profit is expected to increase by 20 to 28 per cent, below an earlier forecast of 22 to 30 per cent.
